SAR446268
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SAR446268, covering 2026-02-02 to 2026-02-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1 [Phase 1, Phase 2]